Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS-02
- Development stage
- Preclinical
- Lead developer
- Center Laboratories
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CS-02 is a preclinical therapeutic vaccine candidate developed by CelSiege Biosciences for the treatment of various cancers. It utilizes a B cell-mediated immunotherapy platform designed to induce the production of endogenous polyclonal antibodies. These antibodies are intended to transiently deplete overexpressed ligands and cytokines that drive angiogenesis and lymph-angiogenesis within the tumor microenvironment. By neutralizing these growth factors, CS-02 aims to inhibit tumor vascularization and lymphatic spread, thereby suppressing tumor growth and metastasis. The vaccine is administered via intramuscular injection.
02
Targets
VEGFC (VEGF-C)
Beyond the preview
Go deeper on CS-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS-02.